Clinical trials: Flavivirus Infections
Dengue
An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge
The investigational study drug, JNJ-64281802, is being developed for the prevention and treatment of dengue infection. This study is hypothesizing that the highest dose of the investigational study drug is superior to receiving a…
- Trial name
- NCT05048875
- Testing
- Cohort 1 - Group 1 JNJ High Dose, Cohort 1 - Group 2 JNJ Medium Dose, Cohort 1 - Group 2 JNJ Low Dose
- Where
- 2 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue Virus, Dengue Fever
Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years
The aim of the trial was to evaluate the use of a tetravalent vaccine, CYD dengue vaccine, against dengue disease. Primary Objectives: To describe the humoral immune response to dengue before and after each vaccination with…
- Conditions
- Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever, Dengue Diseases
- Trial name
- NCT00788151
- Testing
- CYD Dengue Vaccine Serotypes 1, 2, 3, and 4, Pneumococcal polysaccharide vaccine
- Where
- Peru
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue
Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults
This descriptive study will evaluate the safety and immunogenicity of 3 different formulations of the WRAIR dengue vaccine compared to a placebo.
- Trial name
- NCT00350337
- Testing
- Pre-transfection F17, Post-transfection F17, Post-transfection F19
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Japanese Encephalitis, Varicella
Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV
The aim of the study is to investigate the memory immune response and the yearly persistence of the immunity against Japanese Encephalitis (JE) after vaccination with Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in…
- Trial name
- NCT01190228
- Testing
- JE-CV Vaccine, Varicella Vaccine
- Where
- Philippines
- Volunteers
- 454 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Zika Virus
Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults
This is a phase 1 double-blind, placebo controlled trial designed to evaluate the safety, reactogenicity, and immunogenicity of a single dose of the live attenuated Zika vaccine rZIKV/D4Δ30-713 in adults with no history of…
- Trial name
- NCT03611946
- Testing
- Single dose of rZIKV/D4Δ30-713 (10^3 PFU) via subcutaneous injection (0.5ml), Single dose of rZIKV/D4Δ30-713 (10^4 PFU) via subcutaneous injection (0.5ml)
- Where
- 2 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Japanese Encephalitis
Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country
This is a randomized, open-label Phase 3 study including children aged >9 months to <17 years and 7 months who have been vaccinated with IXIARO in study IC51-323.
- Trial name
- NCT01296360
- Testing
- IXIARO
- Where
- 3 sites in Philippines
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Japanese Encephalitis, Measles
Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers
This study is designed to compare the immunogenicity of Japanese encephalitis chimeric virus vaccine (JE-CV) and measles-mumps-rubella (MMR)vaccine when given together or when given at separate visits 6 weeks apart in toddlers…
- Conditions
- Japanese Encephalitis, Measles, Mumps, Rubella
- Trial name
- NCT01188343
- Testing
- Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus
- Where
- 3 sites in Taiwan
- Volunteers
- 542 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Encephalitis, Japanese Encephalitis
A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers
The purpose of this study is to compare a single dose of Japanese encephalitis (JE) chimeric virus vaccine (JE-CV) with a single dose of SA14-14-2 live vaccine as primary vaccination in infants and toddlers.
- Trial name
- NCT01092507
- Testing
- Japanese encephalitis chimeric virus vaccine (JE-CV), Japanese encephalitis live vaccine (SA14-14-2 vaccine) (CD.JEVAX®)
- Where
- 3 sites in Thailand
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue, Dengue Fever
Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India
The aim of this study is to evaluate the immunogenicity and safety of the CYD dengue vaccine in India adult subjects. Primary Objectives: To describe the neutralizing antibody response to each dengue virus serotype before the…
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever
- Trial name
- NCT01550289
- Testing
- Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus
- Where
- 5 sites in India
- Volunteers
- 189 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Japanese Encephalitis
Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine
To facilitate introduction of live attenuated SA 14-14-2 Japanese encephalitis vaccine (LJEV) into the National Immunization Programme of Sri Lanka, we evaluated the safety and immunogenicity of co-administration of LJEV and…
- Trial name
- NCT00463476
- Testing
- Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV)
- Where
- 3 sites in Sri Lanka
- Volunteers
- 305 people, healthy volunteers welcome
- Sponsor
- PATH
Zika Virus Infection
Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001)
This study is designed to investigate, at first, safety and tolerability of a novel liquid vaccine formulation named MV-ZIKA-RSP, in healthy adults aged 18 to 55 years
- Trial name
- MV-ZIKA-RSP (NCT04033068)
- Testing
- Two MV-ZIKA-RSP vaccinations (high dose), Two MV-ZIKA-RSP vaccination (low dose)
- Where
- Austria
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Themis Bioscience GmbH
Viral Infection
Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects
The objective is to evaluate the safety and tolerability of a single-ascending oral dose of UV-4B in healthy subjects and to determine pharmacokinetic parameters describing absorption and elimination following a single dose of…
- Trial name
- UV (NCT02061358)
- Testing
- UV-4B 3 mg, UV-4B 10 mg, UV-4B 30 mg
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Healthy
GLS-5700 in Dengue Virus-Naïve Adults
The clinical trial will assess the safety, tolerability, and immunogenicity of GLS-5700. GLS-5700 is a synthetic DNA plasmid vaccine against the Zika virus.
- Trial name
- NCT02809443
- Testing
- GLS-5700
- Where
- 3 sites in United States, Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
Japanese Encephalitis
Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study
The study investigates long-term immunity and safety of IC51 (IXIARO®, JESPECT®) in a pediatric population vaccinated in the parent study IC51-322.
- Trial name
- NCT01246479
- Testing
- Blood draw, IC51 has given in the parent study IC51-322
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Dengue, Dengue Fever
Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine
The aim of the study was to evaluate a compressed dosing schedule and the immunologic effects of co-administration of a CYD dengue vaccine with a licensed flavivirus (FV) with Japanese encephalitis (JE) vaccine.
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever
- Trial name
- NCT01943825
- Testing
- CYD Dengue Vaccine, Japanese Encephalitis Vaccine
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue, Dengue Hemorrhagic Fever
Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
The study was designed to evaluate whether the first CYD dengue vaccination can be administered concomitantly with Stamaril® yellow fever vaccine during the same day and visit, but at 2 different sites of administration.
- Conditions
- Dengue, Dengue Hemorrhagic Fever, Yellow Fever
- Trial name
- NCT01436396
- Testing
- Live, attenuated dengue serotype 1, 2, 3, and 4 virus, Yellow fever vaccine, Measles, mumps, and rubella (MMR) vaccine
- Where
- 2 sites in Colombia, Peru
- Volunteers
- 792 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue
A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants
The main target populations for the tetravalent live attenuated dengue virus vaccine are indigenous populations, especially infants less than 2 years old, residing in areas of the world endemic for dengue and at risk of…
- Trial name
- NCT00322049
- Testing
- Tetravalent live attenuated dengue vaccine, Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine
- Where
- Thailand
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Healthy Volunteers
A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers
AV-1 is a human monoclonal antibody (mAb) being investigated as a potential therapy for dengue, a mosquito-borne viral disease with extensive global public health impact.
- Trial name
- NCT04273217
- Testing
- AV-1
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- AbViro LLC
Dengue Fever
Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants
The purpose of this study is to assess the humoral immune responses to three different dose schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) administered subcutaneously in healthy participants between 2 and <18…
- Trial name
- NCT02302066
- Testing
- Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
- Where
- 3 sites in Dominican Republic, Panama and 1 more
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue Fever
Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore
The purpose of this study is to assess the post-vaccination neutralizing antibody response against each dengue serotype by vaccine group.
- Trial name
- NCT02425098
- Testing
- Takeda's Tetravalent Dengue Vaccine Candidate (TDV), Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)
- Where
- 3 sites in Singapore
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- Takeda